GCG, glucagon, 2641

N. diseases: 441; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.340 Therapeutic disease CTD_human Increase of serum very low density lipoproteins in rats after administration of alpha-hexachlorocyclohexane. 69995 1977
CUI: C1706412
Disease: Lipidemias
Lipidemias 		0.300 Therapeutic phenotype CTD_human Increase of serum very low density lipoproteins in rats after administration of alpha-hexachlorocyclohexane. 69995 1977
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.400 GeneticVariation disease BEFREE An abnormality of circulating glucagon found in one child with this disorder suggested that hyperinsulinism may not be the sole hormonal imbalance present, but rather that this disease is one of generalized disturbance of islet cell function. 383929 1979
CUI: C0948379
Disease: Impaired insulin secretion
Impaired insulin secretion 		0.060 Biomarker disease BEFREE Turner's syndrome and carbohydrate metabolism. I. Impaired insulin secretion after tolbutamide and glucagon stimulation tests: evidence of insulin deficiency. 463942 1979
CUI: C0041408
Disease: Turner Syndrome
Turner Syndrome 		0.010 Biomarker disease BEFREE Turner's syndrome and carbohydrate metabolism. I. Impaired insulin secretion after tolbutamide and glucagon stimulation tests: evidence of insulin deficiency. 463942 1979
CUI: C0242526
Disease: Gonadal Dysgenesis, 45,X
Gonadal Dysgenesis, 45,X 		0.010 Biomarker disease BEFREE Tolbutamide (25 mg/kg: maximum 1 mg) intravenously (IV) and glucagon (0.03 mg/kg; maximum 1 mg) intramuscularly (IM) were given sequentially to 12 untreated girls with XO-Turner's syndrome (ages 6.5 to 17.0 years) and to ten female siblings (ages 8.0 to 16.7 years) to evaluate blood sugar (BS), plasma free fatty acids (FFA), serum immunoreactive insulin (IRI), and growth hormone (IRGH) responses to these insulinogenic secretagogues in order to appreciate any differences of genotypes on carbohydrate metabolism within identical family backgrounds. 463942 1979
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.400 Biomarker disease BEFREE Plasma glucose, insulin, glucagon, and growth hormone in kindreds with maturity-onset type of hyperglycemia in young people. 646240 1978
CUI: C0342637
Disease: Hypocalciuric hypercalcemia, familial, type 1
Hypocalciuric hypercalcemia, familial, type 1 		0.010 Biomarker disease BEFREE Concentrations of peptide hormones other than parathyroid hormone (PTH) were normal in those with FHH; in FMEN I high concentrations of glucagon in plasma were found in five of six patients tested, and high concentrations of gastrin were found in three of 12 patients. 871127 1977
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.400 Biomarker disease BEFREE In contrast to 8 normal subjects and the remaining 10 first-degree relatives the secretion of glucagon by the 5 first degree relatives with abnormally low insulin release was not suppressed by induced hyperglycaemia. 1092713 1975
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 AlteredExpression group BEFREE Diabetes mellitus is characterized by insulin deficiency and high plasma glucagon levels, which can be normalized by insulin replacement. 1651499 1991
CUI: C0032580
Disease: Adenomatous Polyposis Coli
Adenomatous Polyposis Coli 		0.010 Biomarker disease BEFREE Upon oral administration of a loading dose of glucose, plasma levels of glucose, insulin and glucagon changed abnormally in all FAP patients tested. 1940028 1991
CUI: C2751492
Disease: AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED 		0.010 Biomarker disease BEFREE Upon oral administration of a loading dose of glucose, plasma levels of glucose, insulin and glucagon changed abnormally in all FAP patients tested. 1940028 1991
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE In the subjects who progressed to diabetes, the responses to glucose and glucagon were similarly blunted. 1955097 1991
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 Biomarker group BEFREE In the subjects who progressed to diabetes, the responses to glucose and glucagon were similarly blunted. 1955097 1991
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.100 Biomarker disease BEFREE Acute insulin response to intravenous glucose, glucagon and arginine in some subjects at risk for type 1 (insulin-dependent) diabetes mellitus. 1955097 1991
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The nature of selective hyper-expression of HMG-17 in glucagon but not in insulin-producing tumor tissue remains to be clarified. 2169420 1990
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.100 Biomarker disease BEFREE Because the B-cell response to glucose was not less than that to glucagon, a selective destruction of the glucose recognition system cannot be a characteristic of all twins throughout the period before they develop Type 1 diabetes. 2687066 1989
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE The pluripotent rat islet tumor cell line MSL-G2 expresses primarily glucagon or cholecystokinin and not insulin in vitro but changes phenotype completely after prolonged in vivo cultivation to yield small-sized hypoglycemic tumors composed almost entirely of insulin-producing beta cells. 2842785 1988
CUI: C0017925
Disease: Glycogen Storage Disease Type VI
Glycogen Storage Disease Type VI 		0.010 AlteredExpression disease BEFREE Human liver glycogen phosphorylase deficiency, also known as glycogen storage disease type VI (GSD VI) or Hers disease, is characterized by hepatomegaly and reduced or absent glycogenolytic response to the injection of glucagon. 2883891 1987
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE By analyses of RNA transcripts and immunoreactive peptides in four human insulinomas and one glucagonoma, we found that the insulin, somatostatin, and glucagon genes were coexpressed in all tumors. 2903836 1988
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.400 Therapeutic disease CTD_human Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. 3019152 1986
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.400 Biomarker disease CTD_human Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. 3019152 1986
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.400 Biomarker disease CTD_human Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. 3019152 1986
CUI: C1257963
Disease: Endogenous Hyperinsulinism
Endogenous Hyperinsulinism 		0.300 Biomarker disease CTD_human Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. 3019152 1986
CUI: C1257964
Disease: Exogenous Hyperinsulinism
Exogenous Hyperinsulinism 		0.300 Biomarker disease CTD_human Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. 3019152 1986